Category Archives: Inside BIO Industry Analysis

IPO UPDATE – JANUARY 4th, 2011

In 2010 we saw the return of the Biotech IPO. In the US, 17 biotech companies went public, up from 3 in 2009, and only 1 in 2008. However, almost all of them had to accept a lower price than was sought in the initial filing. The average downward adjustment to the amount raised was 25%. The median and mean amount raised in the US in 2010 was $53M and $84M, respectively. Since the IPO Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

How Profitable is the Biotech Drug Development Sector?

Q: How many public biotechnology companies focused on pursuing drug development are profitable? A: Less than 10% Of 225 public biotech companies in the drug development business, only 17 are profitable (7.5%) based on 2009 Net Income. The profitable companies tend to be those with three or more products: Only 1.3% have 1 product AND are profitable (3 of 225) Only 0.9% have 2 products AND make a profit (2 of 225) Only 5.3% have Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Update – Analysis of Therapeutic Discovery Project Awards

Here are the results from our recent analysis of the Therapeutic Discovery Project. (For additional background and links on the TDP, please see our previous post from Nov 3rd, 2010.) The 4,606 projects that were awarded a TDP grant or credit went to 2,923 companies in 47 states. That averages to 1.6 projects per company. A more detailed analysis reveals that the majority (72%) of the companies received one project credit or grant, and 28% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Clinical Trial Success Rates – Recent Study from Tufts

Joseph DiMasi and his team at Tufts University published a paper earlier this year in Nature’s Clinical Pharmacology & Therapeutics journal that contains some interesting data on clinical trial success rates. The published data are relevant to biotech investors and business development professionals in that published industry data for clinical outcomes can make a significant difference on the overall valuation of a company. These probabilities can also have a meaningful impact on the ability to Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

IPO Update – November 11th, 2010

Today’s IPO from Complete Genomics (GNOM) brings the US biotech IPO list to 17 since the latest window opened up back in August 2009. The Complete Genomics IPO makes it two in a row for DNA sequencing companies hitting the Nasdaq, with Pacific Biosciences (PACB) debuting just 10 trading days ago. Once again, however, we see the IPO price come in below the expected price: Complete Genomics priced its initial public offering of stock at Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,